Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GSK American Depositary Shares Representing 2 Ordinary Shares GSK

Consumer Cyclical
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also... see more

Recent & Breaking News (NYSE:GSK)

GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer

Business Wire October 23, 2019

GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma

Business Wire October 2, 2019

GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)

PR Newswire September 28, 2019

Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma

Business Wire September 12, 2019

Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options

Business Wire June 6, 2019

The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing

Benzinga.com  April 9, 2019

Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Benzinga.com  March 29, 2019

Markets React Amid Report FDA Commish Scott Gottlieb Will Resign

Benzinga.com  March 5, 2019

Q4 Earnings Outlook For GlaxoSmithKline

Benzinga.com  February 5, 2019

Pharma Catches Another Case Of M&A Fever

Benzinga.com  February 1, 2019

TD Ameritrade IMX Continued Its Dip In December, Falling To A More Than Two-Year Low

Benzinga.com  January 8, 2019

FinancialBuzz.com: 'Federal Reserve Raises Interest Rates' Video Recap Week Ending December 21st, 2018

PR Newswire December 21, 2018

GlaxoSmithKline, Pfizer To Merge Consumer Health Care Businesses

Benzinga.com  December 19, 2018

Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company

Business Wire December 19, 2018

Financialbuzz.com: 'Trade War Cease Fire' Video Recap Week Ending December 7th, 2018

PR Newswire December 7, 2018

Explosion of Latest Clinical Studies and Results Reinvigorating Immunotherapy Market

PR Newswire December 4, 2018

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Tesaro, Inc. (TSRO) on Behalf of Stockholders and Encourages TSRO Investors to Contact the Firm

GlobeNewswire December 3, 2018

Mid-Afternoon Market Update: Tesaro Climbs On Acquisition News; Tonix Pharmaceuticals Shares Slide

Benzinga.com  December 3, 2018

46 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  December 3, 2018

Mid-Day Market Update: Hexindai Falls After Q2 Results; Global Blood Therapeutics Shares Surge

Benzinga.com  December 3, 2018